Fate Therapeutics Inc (NASDAQ: FATE) kicked off on Monday, up 16.53% from the previous trading day, before settling in for the closing price of $1.21. Over the past 52 weeks, FATE has traded in a range of $0.66-$3.50.
Healthcare Sector giant saw their annual sales slid by -2.63% over the last five years. While this was happening, its average annual earnings per share was recorded 26.83%. With a float of $109.47 million, this company’s outstanding shares have now reached $114.66 million.
Fate Therapeutics Inc (FATE) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Fate Therapeutics Inc is 5.08%, while institutional ownership is 70.53%. The most recent insider transaction that took place on Aug 04 ’25, was worth 9,573. In this transaction an insider of this company sold 9,037 shares at a rate of $1.06, taking the stock ownership to the 397,670 shares. Before that another transaction happened on Aug 04 ’25, when Company’s President and CEO sold 14,466 for $1.06, making the entire transaction worth $15,396. This insider now owns 334,898 shares in total.
Fate Therapeutics Inc (FATE) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.4 earnings per share (EPS), higher than consensus estimate (set at -0.41) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 26.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.70% during the next five years compared to -2.63% drop over the previous five years of trading.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Take a look at Fate Therapeutics Inc’s (FATE) current performance indicators. Last quarter, stock had a quick ratio of 8.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.45, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach -1.10 in one year’s time.
Technical Analysis of Fate Therapeutics Inc (FATE)
Analysing the last 5-days average volume posted by the [Fate Therapeutics Inc, FATE], we can find that recorded value of 5.3 million was better than the volume posted last year of 2.04 million. As of the previous 9 days, the stock’s Stochastic %D was 71.58%.
During the past 100 days, Fate Therapeutics Inc’s (FATE) raw stochastic average was set at 54.95%, which indicates a significant decrease from 90.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1042 in the past 14 days, which was higher than the 0.0983 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0651, while its 200-day Moving Average is $1.1820. Now, the first resistance to watch is $1.5083. This is followed by the second major resistance level at $1.6067. The third major resistance level sits at $1.7533. If the price goes on to break the first support level at $1.2633, it is likely to go to the next support level at $1.1167. Should the price break the second support level, the third support level stands at $1.0183.
Fate Therapeutics Inc (NASDAQ: FATE) Key Stats
The company with the Market Capitalisation of 162.61 million has total of 115,330K Shares Outstanding. Its annual sales at the moment are 13,630 K in contrast with the sum of -186,260 K annual income. Company’s last quarter sales were recorded 1,910 K and last quarter income was -34,070 K.
